Bergen, Norway – November 6th, 2020: The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership in the German company Digital Diagnostics AG, which has developed an accurate and reliable rapid test for Covid-19.
On October 20th, 2020, Lifecare announced a share exchange agreement related to 25% of Human Data AG holding in Digital Diagnostics. The share exchange agreement does not affect Lifecares holding in Digital Diagnostics.
As assumed by Lifecare the transactions have been subject for approval by Digital Diagnostics.
Digital Diagnostics has convened an extraordinary shareholders’ meeting where 100% of the outstanding shares was represented. 69.9% of the shares voted to decline approval for the share transfer. Human Data, representing 30.1% of the shares, abstained from voting. Consequently, the share transfer from Human Data AG was not approved.
Lifecare wants to inform that one of the founding owners of Digital Diagnostics, IMS Capital GmbH, transferred its shares to Human Data AG March 5th, 2020. All obligations under the Joint Venture agreement related to Digital Diagnostics have been settled by IMS Capital and its successors.
The majority shareholders in Digital Diagnostics are Human Data (30.1%), Lifecare (25%) and VRV AG (20%).
The Board of Directors of Digital Diagnostics consists of Nicolaus von Rintelen (Chairman) – VRV, Dr. Manuel Vogel (Deputy Chairman) – Human Data, Joacim Holter – Lifecare and Prof. Dr. Med. Andreas Pfützner – Islay Venture GmbH.
Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of diabetics’ blood sugar. Its patented technology is also used as a central component in a rapid test for Covid-19 and as a measurement unit for reading out different biomarkers.
For more information, please contact:
+47 40 05 90 40
Access the news on Oslo Bors NewsWeb site